Since 2021, Swiss Re has launched CARE with 11 Korean insurers, applying the solution to the newly released benefits of Targeted Therapy (TT) and Anti-Cancer Hormone Treatment (ACHT)
Through CARE, clients can ensure consistency and accuracy of claim decision making
Addressing client needs
Addressing client needs
CARE has helped our clients solve their most pressing challenges:
Assessors’ lack of technical knowledge of chemotherapy drugs mechanisms and complex drug indications
Ongoing updates on drug indications and introduction of new drugs
Multiple references on chemotherapy drug types
Numerous and complex National Health Insurance schemes on chemotherapy
User experience
User experience
Simple, easy to use platform
Contains the most up-to-date information required for accurate claims assessments, with the drug list of all approved chemotherapy drugs in South Korea regularly updated
Holistic approach: The platform is complemented by technical training for users